Ibrutinib combined with venetoclax treatment outcome in chronic lymphocytic leukemia: A systematic review

被引：0
|
作者：
Sugianto, Jeremy Octavian [1 ]
Purushotama, Nyoman Bagus Satcitta Ananda [1 ]
Ontowirjo, Yudi Ali Putra [1 ]
Sutanto, Mario [1 ]
Kurniawan, Andree [2 ]
机构：
[1] Pelita Harapan Univ, Fac Med, Tangerang, Indonesia
[2] Pelita Harapan Univ, Dept Internal Med, Fac Med, Tangerang, Indonesia
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.345
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P12-9
引用
收藏
页码：S1447 / S1447
页数：1
相关论文
共 50 条
  • [11] Venetoclax for the treatment of chronic lymphocytic leukemia
    Gentile, Massimo
    Petrungaro, Annamaria
    Uccello, Giuseppina
    Vigna, Ernesto
    Recchia, Anna Grazia
    Caruso, Nadia
    Bossio, Sabrina
    De Stefano, Laura
    Palummo, Angela
    Storino, Francesca
    Martino, Massimo
    Morabito, Fortunato
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1307 - 1316
  • [12] Ibrutinib for the treatment of chronic lymphocytic leukemia
    Deodato, Marina
    Frustaci, Anna Maria
    Zamprogna, Giulia
    Cairoli, Roberto
    Montillo, Marco
    Tedeschi, Alessandra
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (05) : 273 - 284
  • [13] Ibrutinib for treatment of chronic lymphocytic leukemia
    Vela, Cory M.
    McBride, Ali
    Jaglowski, Samantha M.
    Andritsos, Leslie A.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (06) : 367 - 375
  • [14] Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
    Herbert Eradat
    Current Hematologic Malignancy Reports, 2019, 14 : 469 - 476
  • [15] Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
    Eradat, Herbert
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (05) : 469 - 476
  • [16] Ibrutinib for the treatment of chronic lymphocytic leukemia
    Farooqui, Mohammed Z. H.
    Wiestner, Adrian
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (11): : 925 - 933
  • [17] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Estrov, Zeev E.
    Sasaki, Koji
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Wang, Wei
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Cruz, Nichole
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2020, 136
  • [18] Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
    Kater, Arnon P.
    Slinger, Erik
    Cretenet, Gaspard
    Martens, Anne W.
    Balasubramanian, Sriram
    Leverson, Joel D.
    Eldering, Eric
    BLOOD ADVANCES, 2021, 5 (23) : 5410 - 5414
  • [19] Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia
    Hampel, Paul J.
    Rabe, Kari G.
    Call, Timothy G.
    Ding, Wei
    Leis, Jose F.
    Kenderian, Saad S.
    Muchtar, Eli
    Wang, Yucai
    Koehler, Amber B.
    Parrondo, Ricardo
    Schwager, Susan M.
    Shi, Min
    Braggio, Esteban
    Slager, Susan L.
    Kay, Neil E.
    Parikh, Sameer A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) : 239 - 244
  • [20] Venetoclax for the treatment of patients with chronic lymphocytic leukemia
    Crombie, Jennifer
    Davids, Matthew S.
    FUTURE ONCOLOGY, 2017, 13 (14) : 1223 - 1232
12345